Immunodeficiency syndrom inhibitor

Pettersen JA, Jones G et al (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients protease inhibitor-mediated neurotoxicity. Ann Neurol... 

Nearly 40 million people are infected with the human immunodeficiency virus (HIV). Over half of those infected reside in sub-Saharan Africa. Worldwide during 2004, it is estimated that nearly 14,000 people a day were infected. Human immunodeficiency virus type 1 is the primary etiological source for the acquired immunodeficiency syndrome (AIDS). Fortunately, people infected with HIV are leading longer and more productive lives due to the availability of more effective therapies. Better medicines have evolved due to the efforts of scientists worldwide who find targets and compounds that inhibit the virus life-cycle. The current treatment for HIV infection is via a drug cocktail that usually includes a protease inhibitor (PI), a nucleoside reverse transcriptase inhibitor (NRTI), and a non-nucleoside reverse transcriptase inhibitor (NNRTI). 

Efavirenz (DMP 266) (1) is an effective non-nucleoside inhibitor of reverse transcriptase of the human immunodeficiency virus (HIV) recently registered by the US Food Drug Administration (FDA) for treatment of the acquired immunodeficiency syndrome (AIDS).1 2 3 Inhibition of HIV reverse transcriptase by nucleosides like azidothymidine (AZT) (2) is a proven therapy for delaying the progression to AIDS. However, the rapid viral mutation to resistant strains requires the development of new therapeutic agents. The recent development of both protease inhibitors and non-nucleoside reverse transcriptase inhibitors offers hope of effective treatment especially when coadministered. 

Angiotensin I converting enzyme Acquired immunodeficiency syndrome Aspartic protease inhibitor Bowman Birk protease inhibitor protein Chymotrypsin Cysteine protease inhibitor Endothelin-converting enzyme Elastase... 

Eng KT, Liu ES, Silverman MS, Berger AR. Lipemia reti-nalis in acquired immunodeficiency syndrome treated with protease inhibitors. Arch Ophthalmol 2000 118(3) 425-6. 

ACEI angiotensin-converting enzyme inhibitor AIDS acquired immunodeficiency syndrome ARB angiotensin receptor blocker... 

Use of histamine-2 blockers and proton pump inhibitors Patients with acquired immunodeficiency syndrome (AIDS) Break in skin barrier Burns... 

NO may play a role in neurodegenerative disorders and other forms of neurotoxicity. NO is an important mediator in central nervous system oxygen toxicity, since inhibitors of NOS protect mice against this toxicity (Oury et al., 1992). NO may play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS) dementia, as the neurotoxicity in primary cortical cultures induced by the human immunodeficiency virus (HIV) coat protein, glycoprotein 120 (Lipton, 1992), is due, in part, to activation of NOS (V. 

A key strategy in the treatment of acquired immunodeficiency syndrome (AIDS) has been to develop specific inhibitors that selectively block the actions of enzymes unique to the human immunodeficiency virus (HIV), which causes AIDS. Many laboratories are working on this approach to the development of therapeutic agents. Three key enzymes are current targets for AIDS therapy—reverse transcriptase, integrase, and protease. 

The client diagnosed with acquired immunodeficiency syndrome (AIDS) is prescribed a combination of a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, and two nucleoside reverse transcriptase inhibitors. Which statement best describes the scientific rationale for combining these medications ... 

Congenital defects and chemical inhibitors of these enzymes result in the accumulation of purine nucleosides and nucleotides which have been directly linked to impaired lymphocyte function and immunodeficiency syndromes (4,5). Since the uremic state is complicated by an increased susceptability to infection largely the result of acquired l3nnphocyte abnormalities, we have studied the ability of uremic erythrocytes (RBC) to metabolize vitro radiolabelled adenosine and deoxyadenosine utilizying a combind UV - radioactive high performance liquid chromatographic technique (HPLC) (1,2,3). 

Abstract Acquired immunodeficiency syndrome (AIDS) and its related disorders, caused by retrovirus human immunodeficiency virus (HIV) are a major health concern worldwide. HIV protease is one of the major viral targets for the development of new chemotherapeutics. Currently, many HIV protease inhibitors are used in combination with HIV reverse transcriptase inhibitors. However, the use of current drugs regimens has several shortcomings, such as adherence, tolerability, long-term toxicity and drug- and... 

---